vs
CRISPR Therapeutics AG（CRSP）与RMR GROUP INC.（RMR）财务数据对比。点击上方公司名可切换其他公司
RMR GROUP INC.的季度营收约是CRISPR Therapeutics AG的1.9倍（$66.7M vs $35.7M），RMR GROUP INC.净利率更高（18.3% vs -104.5%，领先122.8%），RMR GROUP INC.同比增速更快（40.8% vs -82.3%）
CRISPR Therapeutics AG是一家瑞美合资生物技术企业，总部位于瑞士楚格，在美国以CRISPR Therapeutics, Inc.名义开展业务。作为首批依托CRISPR基因编辑平台开发药物的企业之一，公司现有约500名员工，在瑞士楚格、美国波士顿、旧金山及英国伦敦设有办公点，专注于多种罕见病与常见病的治疗药物研发。
RMR集团是总部位于美国的另类资产管理企业，核心业务聚焦不动产及相关投资，覆盖商业地产、住宅物业、基础设施等赛道，服务全球核心市场的机构投资者、高净值人士及零售客户。
CRSP vs RMR — 直观对比
营收规模更大
RMR
是对方的1.9倍
$35.7M
营收增速更快
RMR
高出123.0%
-82.3%
净利率更高
RMR
高出122.8%
-104.5%
损益表 — Q4 FY2024 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $35.7M | $66.7M |
| 净利润 | $-37.3M | $12.2M |
| 毛利率 | — | — |
| 营业利润率 | -181.0% | 48.1% |
| 净利率 | -104.5% | 18.3% |
| 营收同比 | -82.3% | 40.8% |
| 净利润同比 | -141.8% | 91.1% |
| 每股收益（稀释后） | $-0.41 | $0.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRSPRMR
| Q4 25 | — | $66.7M | ||
| Q4 24 | $35.7M | — | ||
| Q4 23 | $201.2M | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $70.0M | — | ||
| Q1 23 | $100.0M | — |
净利润CRSPRMR
| Q4 25 | — | $12.2M | ||
| Q4 24 | $-37.3M | — | ||
| Q4 23 | $89.3M | — | ||
| Q3 23 | $-112.2M | — | ||
| Q2 23 | $-77.7M | — | ||
| Q1 23 | $-53.1M | — |
营业利润率CRSPRMR
| Q4 25 | — | 48.1% | ||
| Q4 24 | -181.0% | — | ||
| Q4 23 | 34.6% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -136.0% | — | ||
| Q1 23 | -64.5% | — |
净利率CRSPRMR
| Q4 25 | — | 18.3% | ||
| Q4 24 | -104.5% | — | ||
| Q4 23 | 44.4% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -111.1% | — | ||
| Q1 23 | -53.1% | — |
每股收益（稀释后）CRSPRMR
| Q4 25 | — | $0.71 | ||
| Q4 24 | $-0.41 | — | ||
| Q4 23 | $1.12 | — | ||
| Q3 23 | $-1.41 | — | ||
| Q2 23 | $-0.98 | — | ||
| Q1 23 | $-0.67 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9B | $49.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $232.7M |
| 总资产 | $2.2B | $687.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRSPRMR
| Q4 25 | — | $49.3M | ||
| Q4 24 | $1.9B | — | ||
| Q4 23 | $1.7B | — | ||
| Q3 23 | $1.7B | — | ||
| Q2 23 | $1.8B | — | ||
| Q1 23 | $1.9B | — |
股东权益CRSPRMR
| Q4 25 | — | $232.7M | ||
| Q4 24 | $1.9B | — | ||
| Q4 23 | $1.9B | — | ||
| Q3 23 | $1.7B | — | ||
| Q2 23 | $1.8B | — | ||
| Q1 23 | $1.9B | — |
总资产CRSPRMR
| Q4 25 | — | $687.1M | ||
| Q4 24 | $2.2B | — | ||
| Q4 23 | $2.2B | — | ||
| Q3 23 | $2.1B | — | ||
| Q2 23 | $2.2B | — | ||
| Q1 23 | $2.2B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-50.0M | $10.7M |
| 自由现金流经营现金流 - 资本支出 | $-50.3M | — |
| 自由现金流率自由现金流/营收 | -140.9% | — |
| 资本支出强度资本支出/营收 | 0.7% | — |
| 现金转化率经营现金流/净利润 | — | 0.88× |
| 过去12个月自由现金流最近4个季度 | $-325.9M | — |
8季度趋势，按日历期对齐
经营现金流CRSPRMR
| Q4 25 | — | $10.7M | ||
| Q4 24 | $-50.0M | — | ||
| Q4 23 | $-96.1M | — | ||
| Q3 23 | $-39.9M | — | ||
| Q2 23 | $-133.2M | — | ||
| Q1 23 | $8.8M | — |
自由现金流CRSPRMR
| Q4 25 | — | — | ||
| Q4 24 | $-50.3M | — | ||
| Q4 23 | $-96.8M | — | ||
| Q3 23 | $-42.0M | — | ||
| Q2 23 | $-136.8M | — | ||
| Q1 23 | $5.7M | — |
自由现金流率CRSPRMR
| Q4 25 | — | — | ||
| Q4 24 | -140.9% | — | ||
| Q4 23 | -48.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -195.4% | — | ||
| Q1 23 | 5.7% | — |
资本支出强度CRSPRMR
| Q4 25 | — | — | ||
| Q4 24 | 0.7% | — | ||
| Q4 23 | 0.4% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 5.1% | — | ||
| Q1 23 | 3.1% | — |
现金转化率CRSPRMR
| Q4 25 | — | 0.88× | ||
| Q4 24 | — | — | ||
| Q4 23 | -1.08× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRSP
| Collaboration Revenue | $35.0M | 98% |
| Grant | $2.3M | 6% |
RMR
| Management Service Incentive | $23.6M | 35% |
| Industrial Logistics Properties Trust | $15.1M | 23% |
| Managed Private Real Estate Capital | $11.1M | 17% |
| Office Properties Income Trust | $5.6M | 8% |
| Other Private Entities | $5.3M | 8% |
| RMR Residential | $3.4M | 5% |
| Sonesta International Hotels Corporation | $2.1M | 3% |
| Investment Advisory Management And Administrative Service | $1.2M | 2% |
